Literature DB >> 27057465

Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy.

Sylvain Ladoire1, David Enot2, Fabrice Andre3, Laurence Zitvogel4, Guido Kroemer5.   

Abstract

It is well established that the anticancer immune response determines the success of anthracycline-based adjuvant chemotherapy of breast cancer. This effect is in part due to the capacity of anthracyclines to induce immunogenic cell death (ICD), a cell death modality that is preceded by autophagy and followed by HMGB1 release. Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.

Entities:  

Keywords:  Breast cancer; histology; HMGB1; immunogenic cell death; LC3B; p62; SQSTM1

Year:  2015        PMID： 27057465      PMCID： PMC4801435          DOI： 10.1080/2162402X.2015.1082706

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  A dual role for autophagy in a murine model of lung cancer.

Authors:  Shuan Rao; Luigi Tortola; Thomas Perlot; Gerald Wirnsberger; Maria Novatchkova; Roberto Nitsch; Peter Sykacek; Lukas Frank; Daniel Schramek; Vukoslav Komnenovic; Verena Sigl; Karin Aumayr; Gerald Schmauss; Nicole Fellner; Stephan Handschuh; Martin Glösmann; Pawel Pasierbek; Michaela Schlederer; Guenter P Resch; Yuting Ma; Heng Yang; Helmuth Popper; Lukas Kenner; Guido Kroemer; Josef M Penninger
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

2.  An immunosurveillance mechanism controls cancer cell ploidy.

Authors:  Laura Senovilla; Ilio Vitale; Isabelle Martins; Maximilien Tailler; Claire Pailleret; Mickaël Michaud; Lorenzo Galluzzi; Sandy Adjemian; Oliver Kepp; Mireia Niso-Santano; Shensi Shen; Guillermo Mariño; Alfredo Criollo; Alice Boilève; Bastien Job; Sylvain Ladoire; François Ghiringhelli; Antonella Sistigu; Takahiro Yamazaki; Santiago Rello-Varona; Clara Locher; Vichnou Poirier-Colame; Monique Talbot; Alexander Valent; Francesco Berardinelli; Antonio Antoccia; Fabiola Ciccosanti; Gian Maria Fimia; Mauro Piacentini; Antonio Fueyo; Nicole L Messina; Ming Li; Christopher J Chan; Verena Sigl; Guillaume Pourcher; Christoph Ruckenstuhl; Didac Carmona-Gutierrez; Vladimir Lazar; Josef M Penninger; Frank Madeo; Carlos López-Otín; Mark J Smyth; Laurence Zitvogel; Maria Castedo; Guido Kroemer
Journal:  Science       Date:  2012-09-28       Impact factor: 47.728

Review 3.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

4.  Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.

Authors:  Sylvain Ladoire; Frédérique Penault-Llorca; Laura Senovilla; Cécile Dalban; David Enot; Clara Locher; Nicole Prada; Vichnou Poirier-Colame; Kariman Chaba; Laurent Arnould; François Ghiringhelli; Pierre Fumoleau; Marc Spielmann; Suzette Delaloge; Marie Laure Poillot; Patrick Arveux; Aicha Goubar; Fabrice Andre; Laurence Zitvogel; Guido Kroemer
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

Review 5.  Consensus guidelines for the detection of immunogenic cell death.

Authors:  Oliver Kepp; Laura Senovilla; Ilio Vitale; Erika Vacchelli; Sandy Adjemian; Patrizia Agostinis; Lionel Apetoh; Fernando Aranda; Vincenzo Barnaba; Norma Bloy; Laura Bracci; Karine Breckpot; David Brough; Aitziber Buqué; Maria G Castro; Mara Cirone; Maria I Colombo; Isabelle Cremer; Sandra Demaria; Luciana Dini; Aristides G Eliopoulos; Alberto Faggioni; Silvia C Formenti; Jitka Fučíková; Lucia Gabriele; Udo S Gaipl; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Nathalia A Giese; Zong Sheng Guo; Akseli Hemminki; Martin Herrmann; James W Hodge; Stefan Holdenrieder; Jamie Honeychurch; Hong-Min Hu; Xing Huang; Tim M Illidge; Koji Kono; Mladen Korbelik; Dmitri V Krysko; Sherene Loi; Pedro R Lowenstein; Enrico Lugli; Yuting Ma; Frank Madeo; Angelo A Manfredi; Isabelle Martins; Domenico Mavilio; Laurie Menger; Nicolò Merendino; Michael Michaud; Gregoire Mignot; Karen L Mossman; Gabriele Multhoff; Rudolf Oehler; Fabio Palombo; Theocharis Panaretakis; Jonathan Pol; Enrico Proietti; Jean-Ehrland Ricci; Chiara Riganti; Patrizia Rovere-Querini; Anna Rubartelli; Antonella Sistigu; Mark J Smyth; Juergen Sonnemann; Radek Spisek; John Stagg; Abdul Qader Sukkurwala; Eric Tartour; Andrew Thorburn; Stephen H Thorne; Peter Vandenabeele; Francesca Velotti; Samuel T Workenhe; Haining Yang; Wei-Xing Zong; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

6.  Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy.

Authors:  Gautier Stoll; David Enot; Bernhard Mlecnik; Jérôme Galon; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-02-27       Impact factor: 8.110

7.  An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.

Authors:  Mickaël Michaud; Xiaoqi Xie; José Manuel Bravo-San Pedro; Laurence Zitvogel; Eileen White; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

8.  Trial watch: Chemotherapy with immunogenic cell death inducers.

Authors:  Erika Vacchelli; Laura Senovilla; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

9.  Immunological effects of chemotherapy in spontaneous breast cancers.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2013-11-14       Impact factor: 8.110

10.  Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set.

Authors:  Abdul Qader Sukkurwala; Sandy Adjemian; Laura Senovilla; Mickaël Michaud; Sabrina Spaggiari; Erika Vacchelli; Elisa Elena Baracco; Lorenzo Galluzzi; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-04-16       Impact factor: 8.110
  10 in total
  18 in total

Review 1.  Conditioning neoadjuvant therapies for improved immunotherapy of cancer.

Authors:  Zachary Benson; Saeed H Manjili; Mehran Habibi; Georgi Guruli; Amir A Toor; Kyle K Payne; Masoud H Manjili
Journal:  Biochem Pharmacol       Date:  2017-08-10       Impact factor: 5.858

2.  Pro-necrotic molecules impact local immunosurveillance in human breast cancer.

Authors:  Gautier Stoll; Yuting Ma; Heng Yang; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2017-04-17       Impact factor: 8.110

Review 3.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 4.  A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers.

Authors:  Oliver Kepp; Allan Sauvat; Marion Leduc; Sabrina Forveille; Peng Liu; Liwei Zhao; Lucillia Bezu; Wei Xie; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-04-26       Impact factor: 8.110

5.  Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma.

Authors:  Juliana Cano-Mejia; Michelle L Bookstaver; Elizabeth E Sweeney; Christopher M Jewell; Rohan Fernandes
Journal:  Biomater Sci       Date:  2019-04-23       Impact factor: 6.843

6.  Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression.

Authors:  Giorgia Centonze; Dora Natalini; Alessio Piccolantonio; Vincenzo Salemme; Alessandro Morellato; Pietro Arina; Chiara Riganti; Paola Defilippi
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

7.  A dual-responsive doxorubicin-indoximod conjugate for programmed chemoimmunotherapy.

Authors:  Zhaoxuan Yang; Jiaqi Huang; Yaying Lin; Xiangjie Luo; Haojin Lin; Hongyu Lin; Jinhao Gao
Journal:  RSC Chem Biol       Date:  2022-05-30

Review 8.  Classes of therapeutics to amplify the immune response.

Authors:  Yang Hu; Mark E Burkard
Journal:  Breast Cancer Res Treat       Date:  2021-11-17       Impact factor: 4.624

9.  Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes.

Authors:  Feng-Ying Huang; Jing Lei; Yan Sun; Fei Yan; Bin Chen; Liming Zhang; Zhuoxuan Lu; Rong Cao; Ying-Ying Lin; Cai-Chun Wang; Guang-Hong Tan
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

Review 10.  Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer.

Authors:  Amir Sherif; Malin Winerdal; Ola Winqvist
Journal:  Bladder Cancer       Date:  2018-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.